Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis. I think a survey like ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in ...
Intertriginous plaque psoriasis, also known as inverse psoriasis, affects approximately 20%–30% of individuals who have plaque psoriasis. The treatment for plaque psoriasis in intertriginous areas is ...
Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study. Once-daily roflumilast cream 0.3% in adults with chronic plaque psoriasis ...
The US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, "including intertriginous areas," in patients aged 12 years and older.
The woman had axillary granular parakeratosis (GP), a benign condition. First described in 1991, this disease presents with erythematous hyperpigmented and hyperkeratotic papules and plaques in ...
A 55-year-old woman was referred to the dermatology department for an intertriginous eruption of one week’s duration. She had undergone breast-conserving surgery for stage 2 breast cancer. Two weeks ...
Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results